See the technology behind ARISTADA, its formulation, and its pharmacology


Alkermes has a deep history of developing proven, long-acting technology platforms

ARISTADA INITIO and ARISTADA are formulations made of aripiprazole lauroxil drug crystals1-3

  • ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil) are created using the same LinkeRx® technology, and their metabolic conversion processes are the same.1-3 However, ARISTADA INITIO is not interchangeable with ARISTADA due to differing pharmacokinetic profiles

ARISTADA INITIO was developed utilizing NanoCrystal® technology3

  • Drug crystals in ARISTADA INITIO are smaller than those in ARISTADA, allowing for faster dissolution3
  • ARISTADA was designed for slow dissolution from the injection site, providing extended release4,5

This proprietary LinkeRx® technology allows for consistent and sustained medication levels throughout the dosing period.4,5

LinkeRx® and the conversion of ARISTADA to aripiprazole

  • LinkeRx® is proprietary technology used to produce a non-ester prodrug of aripiprazole. Using this system, a linker attaches aripiprazole to a fatty acid, creating ARISTADA4,5
  • This covalently bonded modification of aripiprazole is likely converted in vivo by slow dissolution of the drug crystals and subsequent hydrolysis to release aripiprazole4

LinkeRx® technology allows for

  • Regulated absorption and a low peak-to-trough ratio4
  • Sustained release with an extended pharmacokinetic profile4
  • An aqueous suspension in a prefilled syringe that does not require reconstitution2

See the consistent and sustained medication levels provided by ARISTADA

View pharmacokinetics
References: 1. ARISTADA INITIO [package insert]. Waltham, MA: Alkermes, Inc; 2018. 2. ARISTADA [package insert]. Waltham, MA: Alkermes, Inc; 2018. 3. Data on file. Alkermes, Inc. 4. Turncliff R, Hard M, Du Y, Risinger R, Ehrich EW. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159(2-3):404-410. 5. Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. _Mol Pharm._ 2014;11(6):1739-1749.